Group 1 - The core viewpoint of the article highlights the financial performance of Xuantai Pharmaceutical in Q3 2023, indicating a decline in revenue and net profit compared to the previous year [1] - For the first three quarters of 2025, the company's revenue was approximately 331 million yuan, representing a year-on-year decrease of 8.59% [1] - The net profit attributable to shareholders was about 63.46 million yuan, showing a year-on-year decline of 31.45% [1] - The basic earnings per share were reported at 0.14 yuan, which is a decrease of 33.33% year-on-year [1] Group 2 - As of the report date, Xuantai Pharmaceutical's market capitalization stood at 4.9 billion yuan [2]

上海宣泰医药科技股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期比 | | 年初至报告期 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期增 | 年初至报告期末 | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 111,857,737.01 | -22.65 | 331,464,771.67 | -8.59 | | 利润总额 | 18,271,847.20 | - ...

宣泰医药公告，第三季度营收为1.12亿元，同比下降22.65%；净利润为1787.68万元，同比下降 53.47%。前三季度营收为3.31亿元，同比下降8.59%；净利润为6346.25万元，同比下降31.45%。 ...

证券代码：688247 证券简称：宣泰医药 公告编号：2025-046 上海宣泰医药科技股份有限公司自愿披露 关于公司产品拟中选国家药品集中采购的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2025 年 10 月 30 日 拟中选产 品名称 适应症 规格包装 拟中选价 格 供应省份 采购周期 奥拉帕利 片 上 皮 性 卵 巢癌、输卵 管 癌 或 原 发 性 腹 膜 癌 150mg*56 片/盒 188.7 元/盒 广 东 、 安 徽、天津、 甘肃、贵州 自 中 选 结 果 执 行 之 日 起 至 2028 年 12 月 31 日 一、拟中选药品基本情况 的影响。 三、风险提示 公司拟中选产品的采购合同签订等后续事项以及带量采购后市场销售执行 情况尚具有不确定性。公司将密切关注该事项的进展情况并及时履行信息披露义 务，敬请广大投资者谨慎决策，注意防范投资风险。 特此公告。 上海宣泰医药科技股份有限公司董事会 近日，上海宣泰医药科技股份有限公司（以下简称"公司"）参与了国家组 织药品联合采购办公室（以下简称"联采办" ...

Core Viewpoint - XuanTai Pharmaceutical (688247.SH) has participated in the 11th national centralized procurement organized by the National Organization for Drug Procurement Office, with its product Olaparib tablets expected to be selected in this procurement process [1] Group 1 - The company announced its involvement in the national centralized procurement bidding [1] - The procurement results were published on October 28, 2025, indicating the potential selection of Olaparib tablets [1] - The procurement document number for this process is GY-YD2025-1 [1]

Core Viewpoint - XuanTai Pharmaceutical (688247) announced participation in the 11th national centralized drug procurement organized by the National Organization for Drug Procurement Office, with its product Olaparib tablets proposed for selection in this procurement [1] Group 1 - The company participated in the national centralized drug procurement bidding on October 29 [1] - The proposed selection results were published on October 28, 2025 [1] - The product Olaparib tablets is set to be included in this centralized procurement [1]

Group 1 - The company participated in the 11th national centralized procurement organized by the National Organization for Drug Procurement Office [1] - The proposed selection results for the centralized procurement were published on October 28, 2025 [1] - The company's product, Olaparib tablets, is proposed to be selected in this centralized procurement [1]

Core Viewpoint - Multiple shareholders across various companies are planning to reduce their stakes, indicating potential shifts in investor confidence and market dynamics [1] Shareholder Reductions - Wan Ye Enterprise: Shareholder Sanlin Wan Ye plans to reduce a total of 5.2059 million shares [1] - Kesi Technology: Liang Hongjian intends to reduce 1% of the company's shares [1] - Jindan Technology: Guangzhou Chengxin plans to reduce no more than 2.3866 million shares [1] - Xuantai Pharmaceutical: Qihe Venture plans to reduce a total of 3.131 million shares [1] - Hangzhou Jiebai: Chairman and General Manager Bi Ling plans to reduce a total of no more than 375,000 shares [1] - Jialian Biological: Shareholder UBI plans to reduce no more than 3% of shares [1] - Puyuan Information: Liu Yadong and his concerted actions plan to reduce a total of 0.89% of shares [1] - Zhifan Technology: Director Huang Yong plans to reduce no more than 2.9 million shares [1] - Lanshi Heavy Industry: Shareholder Hualing Xianggang plans to reduce no more than 1% of shares [1] - Biyi Micro: Shareholder Fang Guang Erqi plans to reduce a total of 1.50% of shares [1] - Xinghuo Technology: Shareholder Tie Xiaorong plans to reduce a total of 37.2298 million shares [1] - Henglian Shares: Multiple shareholders plan to reduce their stakes [1] - Jucheng Shares: Wuhan Luojia plans to reduce a total of 4.1241 million shares [1] Financial Performance - Xuanji Information: Reported a net loss of 173 million yuan for the first three quarters [1] - Meilixin: Reported a net loss of 110 million yuan for the third quarter [1]

格隆汇10月22日丨宣泰医药(688247.SH)公布，近日，公司收到持股5%以上股东栖和创业的通知，依照 已披露的减持计划，2025年8月5日至2025年10月22日，栖和创业合计减持公司股份313.1万股，占公司 总股本的比例由5.6907%减少至5.0000%，权益变动触及1%刻度及减持至5%。 ...

一、 信息披露义务人及其一致行动人的基本信息 1.身份类别 证券代码：688247 证券简称：宣泰医药 公告编号：2025-045 上海宣泰医药科技股份有限公司 关于持股 5%以上股东 减持至 5%的权益变动提示性公告 南京市栖和创业投资合伙企业（有限合伙）保证向本公司提供的信息真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 | 投资者名称 | 变动前股数 | 变动前比 | 变动后股数 | 变动后 | 权益变动 | | 权益变动的 | | --- | --- | --- | --- | --- | --- | --- | --- | | | （万股） | 例（%） | （万股） | 比例 （%） | 方式 | | 时间区间 | | 南京市栖和 创业投资合 伙企业（有 | 3,679.8000 | 8.12 | 2,266.7000 | 5.00 | 集中竞价 大宗交易 其他：____ | √ √ | 2025/1/21- 2025/10/22 | | 限合伙） | | | | | | | | | 合计 | 3,679.8000 | ...